The FDA has approved Lynkuet, a 60-milligram capsule therapy from Bayer, for the treatment of moderate to severe hot flashes due to menopause.
Lynkuet is the first dual neurokinin-1 and neurokinin-3 receptor antagonist approved for this indication. The once-daily, nonhormonal medication works by modulating thermoregulation through targeted receptor inhibition.
Approval was based on data from three phase 3 clinical trials — Oasis 1, 2 and 3 — involving 1,420 women, according to an Oct. 24 news release. In Oasis 1 and 2, Lynkuet met co-primary endpoints at weeks 4 and 12 by significantly reducing the frequency and severity of hot flashes among 796 participants. Oasis 3 included 627 women and assessed safety over 52 weeks.
Lynkuet is expected to be available in the U.S. in November 2025.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
